J&J's Supplement Step With Zarbees Helps Drive A Leap For Consumer Health Growth
This article was originally published in The Rose Sheet
Executive Summary
Supplement brand being marketed to compete with OTC drugs, including J&J's own brands, in cough and cold and other categories helped J&J overall consumer health sales grow 9.7% to $440m in Q3. Oral care brands showed 3.2% worldwide growth to $384m, benefiting from recent launch of chewable Listerine Ready! Tabs.
You may also be interested in...
J&J Consumer Health Has Digital And Natural Drivers For ‘Above Market’ Growth
OTC drug sales grew worldwide 4.4% on an operational basis to $4.34bn, with US segment driving increase. US OTC sales jumped 7.8% to reach $1.85bn and international sales grew 2.1% to $2.48bn. J&J consumer segment got a lift from mid-year addition of Zarbees.
J&J CEO Sees Victory Ahead On Talc, Growth From Johnson's Relaunch
JP Morgan analysts had questions and J&J CEO Alex Gorsky and CFO Joseph Wolk had answers about liability suits alleging that use of the Johnson's brand talcum powder has caused mesothelioma or ovarian cancer. On the Johnson's brand outlook following its relaunch as a natural product line, Gorsky says sales were a key driver in the firm's consumer health sales in the 2018 third quarter. China, meanwhile, is a model for growing sales online, he says.
J&J’s Mesquita predicts market shift
“The OTC market of the future may not necessarily be the OTC of the past,” predicted Johnson & Johnson (J&J) Consumer head, Jorge Mesquita, at the Barclays Global Consumer Staples Conference.